Peak6 Investments LLC Apellis Pharmaceuticals, Inc. Call Options Transaction History

Peak6 Investments LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 14, 2024	SELL	$55.39 - $72.47 $858,545 - $1.12 Million	-15,500 Reduced 88.57%	2,000 $117,000
Q4 2023 Feb 13, 2024	SELL	$37.14 - $64.82 $1.17 Million - $2.04 Million	-31,400 Reduced 64.21%	17,500 $1.05 Million
Q3 2023 Nov 13, 2023	BUY	$23.65 - $89.22 $1.11 Million - $4.19 Million	47,000 Added 2473.68%	48,900 $1.86 Million
Q2 2023 Aug 11, 2023	SELL	$76.68 - $93.31 $1.68 Million - $2.04 Million	-21,900 Reduced 92.02%	1,900 $173,000
Q1 2023 May 12, 2023	BUY	$46.59 - $66.96 $1.11 Million - $1.59 Million	23,800 New	23,800 $1.57 Million
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $2.62 Million - $4.08 Million	58,500 New	58,500 $4 Million

302

112M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.19B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Peak6 Investments LLC, based on Form 13F filings with the SEC.

Stay updated on Peak6 Investments LLC with notifications on news.